Debt-free Balance SheetA debt-free balance sheet materially lowers refinancing and interest burden risks, giving management flexibility to fund discovery programs, pursue selective collaborations, or withstand periods without milestone receipts. This strengthens the firm's runway and strategic optionality over the medium term.

Profitability Inflection (2025)Returning to sustained profitability and material revenue growth in 2025 validates the company’s ability to convert discovery work into partnerable outcomes and improves internal funding capacity. Durable profits increase bargaining power for deals and reduce reliance on dilutive financing over the coming months.

Partner/licensing Business ModelA capital-efficient model focused on out-licensing early-stage programs leverages partners for costly clinical development and commercialization. This lets Sprint concentrate on discovery, scale output without heavy capex, and generate milestone/royalty streams that can produce lumpy but high-ROI cash inflows over time.

Bears Say

Lumpy Cash Flow ProfileOperating and free cash flow improved sharply in 2025, but historical unevenness shows milestone timing drives receipts. That lumpiness complicates budgeting and working-capital planning, increases the chance of episodic financing needs, and makes multi-quarter forecasting and resource allocation less predictable.

Reliance On Partner ExecutionRevenue largely hinges on third-party partners advancing licensed programs to trigger milestones and royalties. Sprint has limited control over partners' clinical, regulatory, and commercial decisions, so partner reprioritization, trial failures, or licensing disputes can materially delay or reduce expected future cash flows.

Historical Profitability VolatilityThe swing from recurring losses to a strong 2025 profit highlights outcome variability inherent in early-stage biotech. This historical instability in earnings and equity levels increases risk that positive 2025 results may not be sustained, complicating long-term planning and partner/investor confidence across 2–6 months.

SPRINT FAQ

What was Sprint Bioscience AB’s price range in the past 12 months?

Sprint Bioscience AB lowest stock price was kr0.36 and its highest was kr2.35 in the past 12 months.

What is Sprint Bioscience AB’s market cap?

Sprint Bioscience AB’s market cap is kr198.90M.

When is Sprint Bioscience AB’s upcoming earnings report date?

Sprint Bioscience AB’s upcoming earnings report date is May 13, 2026 which is in 64 days.

How were Sprint Bioscience AB’s earnings last quarter?

Sprint Bioscience AB released its earnings results on Feb 11, 2026. The company reported kr1.073 earnings per share for the quarter, beating the consensus estimate of N/A by kr1.073.

Is Sprint Bioscience AB overvalued?

According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sprint Bioscience AB pay dividends?

Sprint Bioscience AB does not currently pay dividends.

What is Sprint Bioscience AB’s EPS estimate?

Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sprint Bioscience AB have?

Sprint Bioscience AB has 105,515,540 shares outstanding.

What happened to Sprint Bioscience AB’s price movement after its last earnings report?

Sprint Bioscience AB reported an EPS of kr1.073 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of Sprint Bioscience AB?

Currently, no hedge funds are holding shares in SE:SPRINT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sprint Bioscience AB

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.